Regulatory PathRegulatory requirements compared

Active substance

Halobetasol

Open in the medicines table

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
HALOBETASOL PROPIONATE0.05%ointment · topicalPADAGIS ISRAELPrescription16 Dec 2004
HALOBETASOL PROPIONATE0.05%cream · topicalFOUGERA PHARMSPrescription16 Dec 2004
HALOBETASOL PROPIONATE0.05%cream · topicalPADAGIS ISRAELPrescription16 Dec 2004
HALOBETASOL PROPIONATE0.05%ointment · topicalCOSETTE PHARMS NCPrescription14 Jun 2005
HALOBETASOL PROPIONATE0.05%cream · topicalCOSETTE PHARMS NCPrescription24 Apr 2007
ULTRAVATE0.05%lotion · topicalLACER PHARMAPrescription6 Nov 2015
HALOBETASOL PROPIONATE0.05%ointment · topicalENCUBEPrescription20 Mar 2018
BRYHALI0.01%lotion · topicalBAUSCHPrescription6 Nov 2018
HALOBETASOL PROPIONATE0.05%ointment · topicalQUAGENPrescription6 Oct 2020
HALOBETASOL PROPIONATE0.05%aerosol, foam · topicalPADAGIS ISRAELPrescription11 Aug 2023
ULTRAVATE0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**ointment · topicalSUN PHARM INDS INCDiscontinued17 Dec 1990
ULTRAVATE0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**cream · topicalSUN PHARM INDS INCDiscontinued27 Dec 1990
HALOBETASOL PROPIONATE0.05%ointment · topicalFOUGERA PHARMSDiscontinued16 Dec 2004
HALOBETASOL PROPIONATE0.05%ointment · topicalSUN PHARMA CANADADiscontinued16 Dec 2004
HALOBETASOL PROPIONATE0.05%cream · topicalSUN PHARMA CANADADiscontinued4 Aug 2005
HALOBETASOL PROPIONATE0.05%ointment · topicalCOSETTE PHARMS NCDiscontinued7 Sep 2006
LEXETTE0.05%aerosol, foam · topicalMAYNE PHARMADiscontinued24 May 2018
HALOBETASOL PROPIONATE0.05%lotion · topicalPADAGIS ISRAELDiscontinued3 Jun 2020

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
BRYHALI025062620.01 % / W/WLOTION · TOPICALBAUSCH HEALTH, CANADA INC.
ULTRAVATE019627010.05 % / W/WCREAM · TOPICALBAUSCH HEALTH, CANADA INC.
ULTRAVATE019627280.05 % / W/WOINTMENT · TOPICALBAUSCH HEALTH, CANADA INC.

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
US NADACHALOBETASOL PROP 0.05% CREAM$0.648per GM23 Sep 2026
US NADACHALOBETASOL PROP 0.05% CREAM$0.40852per GM23 Sep 2026
US NADACHALOBETASOL PROP 0.05% OINTMNT$0.84285per GM23 Sep 2026
US NADACHALOBETASOL PROP 0.05% OINTMNT$0.39724per GM23 Sep 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Safety signals and safety-related labeling changes

All safety entries for halobetasol →

Combinations containing Halobetasol

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.